Material Agreement (Form 8-K)

Item 1.01 Entry into a Material Definitive Agreement.

Amended and Restated Sales Agreement

As previously reported, on August 13, 2025, ETHZilla Corporation (formerly 180 Life Sciences Corp.) (the "Company") entered into a Sales Agreement (the "Initial Sales Agreement") with Clear Street LLC (the "Agent"), acting as sales agent for the Company's "at the market offering" program. On August 22, 2025, the Company entered into an Amended and Restated Sales Agreement (the "Sales Agreement") to sell from time to time through the Agent, acting as sales agent, shares of the Company's common stock, par value $0.0001 per share (the "Common Stock"), having an aggregate offering price of up to $10.0 billion. The shares of Common Stock will be issued pursuant to the Company's automatic shelf registration statement on Form S-3 (File No. 333-289811), filed with the Securities and Exchange Commission ("SEC") on August 22, 2025 (the "Registration Statement"), a base prospectus dated August 22, 2025, included as part of the Registration Statement, and a prospectus supplement dated August 22, 2025 (the "Prospectus Supplement"), filed by the Company with the SEC pursuant to Rule 424(b) under the Securities Act. Following the execution of the Sales Agreement, the Company may not make any offers or sales of its Common Stock pursuant to at-the-market offering prospectus initially filed on August 13, 2025. The Company issued and sold 5,001,310 shares of Common Stock for aggregate gross proceeds of approximately $34.4 million under the Initial Sales Agreement.

Upon delivery of a placement notice and subject to the terms and conditions of the Sales Agreement, the Agent may sell the Common Stock in negotiated transactions or transactions that are deemed to be an "at the market offering" as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended (the "Securities Act"), including sales made directly on the principal market on which the Common Stock is listed or any other existing trading market for the Common Stock.

The Company will designate the maximum amount of Common Stock to be sold through the Agent in any placement under the Sales Agreement. Subject to the terms and conditions of the Sales Agreement, the Agent has agreed to use its commercially reasonable efforts consistent with its normal trading and sales practices and applicable law and regulations, to sell on the Company's behalf all of the shares of Common Stock requested to be sold by the Company. The Company may instruct the Agent not to sell Common Stock if the sales cannot be effected at or above a price designated by the Company in a placement notice. The Company or the Agent may suspend the offering of Common Stock pursuant to the Sales Agreement upon proper notice to the other party. The Company and the Agent each have the right, by giving 10 days' notice as specified in the Sales Agreement, to terminate the Sales Agreement in each party's sole discretion at any time. The Agent, subject to mutual agreement between the Agent and the Company, may also sell shares of Common Stock sold to it as principal by any other method permitted by law, including, but not limited to, privately negotiated transactions and block trades. The Company also may sell shares of Common Stock to the Agent as principal for its own account, at a price agreed upon at the time of sale. If the Company sells Common Stock to the Agent as principal, it will enter into a separate terms agreement setting forth the terms of such transaction.

The Sales Agreement provides that the Agent will be entitled to aggregate compensation for its services of up to 3.0% of the gross sales price per share of all shares sold through the Agent under the Sales Agreement. The Company has no obligation to sell any shares under the Sales Agreement. In addition, the Company has agreed to reimburse certain legal expenses incurred by the Agent in connection with execution of the Sales Agreement in an amount up to $75,000, in addition to certain ongoing legal expenses.

The Sales Agreement contains customary representations, warranties and covenants by the Company. The Company also agreed to provide indemnification and contribution to the Agent against certain liabilities, including under the Securities Act and the Securities Exchange Act of 1934, as amended. From time to time, in the ordinary course of business, the Agent has provided, and in the future may provide, various financial advisory and investment banking services to the Company, for which they have received or will receive customary fees and reimbursement of expenses. The Agent acted as sales agent in connection with the Initial Sales Agreement and as placement agent in connection with the Company's previously disclosed (i) private placement of approximately $425 million of Common Stock and pre-funded warrants, which closed on August 4, 2025 and (ii) private placement of senior secured convertible notes in the aggregate principal amount of $156,250,000, which closed on August 8, 2025.